MyoGen: Leaders of an Anabolic Revolution
GUJARAT, India, May 23, 2018 (GLOBE NEWSWIRE) -- Myogen will make you rethink what the human body is capable of.
To be an athlete means to partake on a never-ending quest for self-improvement. An obsession to search for a winning edge. Even when we are competing against ourselves, our desire to overcome our physical limitations and achieve new heroic and record setting performances becomes an overwhelming primary focus. Today marks an evolution in what the human body is capable of, with the launch of the MyoGen range of anabolic products.
Myogen, the essence of "muscles".
MyoGen takes its source from the Greek words "Myo" meaning "Muscle" and "Genesis" meaning "Birth". This implicit historical reference, of the origin of the muscle, displays both the commitment and professionalism of Myogen, and their unwavering focus on peak physical performance.
The brightest leader's blaze trails.
The Myogen brand is managed by an international team of experts who are committed to making athletes stronger and faster.
Not only content with producing the highest quality anabolic steroids available, the founders of MyoGen are pushing for total industry reform and improved public perception of performance enhancing compounds.
A radical step into complete transparency
Unlike underground or clandestine laboratories, Myogen reveals everything to the consumer. From the manufacturing process to the marketing of its products, Myogen showcases the smallest detail of its work. This represents an incredible opportunity to discover how pharmaceutical quality products are manufactured. From research and development to manufacturing and testing, MyoGen meets international standards in terms of hygiene and safety.
Myogen is a registered trademark of Gallene Sciences, a global provider of high quality generic drugs, developing innovative and affordable solutions.
Authentic products, proven by science
Myogen offers a complete range of anabolic solutions to suit any goal. Whether you are a professional athlete seeking that performance edge or a fitness enthusiast trying to lose weight or build muscle and strength; MyoGen will change the way you perform with their advanced range of products:
Oral products:
Oxagen10
Dianagen10
Turigen10
Stanogen10
Anagen
Nolvagen
Clomigen
Samagen
Injectables:
Testogen250
Sustagen250
Decagen250
Trenagen Mix 150
Stanogen 50
With Myogen, the body is able to achieve new heights of peak performance in perfect safety. Do not miss this game changing anabolic revolution. Join the Myogen movement
PRESS CONTACT
Gallene Sciences PVT. LTD.9,
Suramya Complex Ahmedabad, Gujarat
380061, India
info@gallenesciences.com
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Gallene Sciences PVT. LTD via Globenewswire
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme19.4.2024 08:39:52 CEST | Press release
To Nasdaq Copenhagen Nykredit Realkredit A/S – New final terms for Euro Medium Term Note Programme Nykredit Realkredit A/S publishes final terms for an issue of SEK 400,000,000 Green Senior Non-Preferred Floating Rate Notes due 2028, which are issued pursuant to Nykredit Realkredit A/S's and Nykredit Bank A/S’s €15,000,000,000 Euro Medium Term Note Programme dated 12 May 2023. The final terms dated 18 April 2024 and the EMTN Programme dated 12 May 2023 are available for download on Nykredit's website at nykredit.com/ir. Enquiries may be addressed to Nykredit Realkredit A/S, Group Treasury, Nicolaj Legind Jensen, Head of Group Treasury, tel +45 44 55 11 10, or Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Attachment Nykredit_Realkredit_New_final_terms_for_Euro_Medium_Term_Note_Programme_2024-04-19
Storaktionærmeddelelse - Danske Andelskassers Bank A/S19.4.2024 08:31:30 CEST | pressemeddelelse
Selskabsmeddelelse nr. 6/2024 | 19. april 2024 Med henvisning til § 30 i lov om kapitalmarkeder oplyses det hermed, at: Jyske Bank har i henhold til § 38 lov om kapitalmarkeder samt bekendtgørelse nr. 1172 af den 31. oktober 2017 om storaktionærer har meddelt til Danske Andelskassers Bank A/S, at Jyske Bank den 18.april 2024 har erhvervet aktier i Danske Andelskassers Bank A/S. Som følge af heraf har Jyske Bank øget deres ejerandel til over 10 % i Danske Andelskassers Bank A/S. Med venlig hilsen Danske Andelskassers Bank A/S Jan Pedersen Adm. direktør Kontaktinformation Henvendelse vedrørende denne meddelelse kan ske til kommunikation- og marketingchef Mette Bernt på telefon 51 87 87 12 eller mail meb@andelskassen.dk. Vedhæftet fil 06-2024 Selskabsmeddelelse - Storaktionærmeddelelse Danske Andelskassers Bank
AKVA group ASA: Invitation – presentation of the Q1 2024 financial results19.4.2024 08:30:09 CEST | Press release
AKVA group ASA hereby invites you to the presentation of the Q1 2024 financial results, which will take place as follows: Time: Friday May 3th, 2024, at 10:00 CET. Webcast: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20240503_1 A recorded version of the presentation will be available after the live stream is concluded. The presentation will be held in English and is open to all interested parties. Dated: 19 April 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagroup.com Ronny MeinkøhnChief Financial OfficerPhone:+47 51 77 85 00Mobile:+47 98 20 67 76E-mail:rmeinkohn@akvagroup.com This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
Update on the acquisition of a block of 71.9% of Believe's share capital and launch of a simplified tender offer for 100% of Believe's share capital.19.4.2024 08:18:00 CEST | Press release
Following the favourable reasoned opinion issued by Believe's Board of Directors, the Consortium confirms its firm and definitive acquisition of nearly 72% of Believe's share capital;All conditions precedent have been definitively fulfilled and the transfer of these shares is firm and irrevocable;This acquisition will be followed by the filing of a simplified tender offer by the Consortium for the remaining shares of Believe, at a price of €15 per share, representing a premium of 43.8% over the volume-weighted average share price of the 30 trading days preceding the announcement of the offer, and at the same price as that obtained by the sellers of the majority blocks; The consortium made up of the EQT X investment fund, the investment funds managed by TCV and the founder and CEO of Believe, Denis Ladegaillerie (the "Consortium") reminds that on 11 February 2024 it entered into agreements with certain historical shareholders of Believe (TCV, XAnge, Ventech and Denis Ladegaillerie) to a
Prosafe SE: Operational Update - April 202419.4.2024 08:13:21 CEST | Press release
Fleet utilization for Q1 2024 was 56 percent. Safe Notos and Safe Zephyrus had utilization of 100 percent in Q1 2024 while Safe Eurus had utilization of 95 percent. Safe Concordia had utilization of 100 percent in Q1 2024 and received 95% day rate until 01 February due to crane repair. Safe Caledonia is laid up at Scapa Flow in the UK pending future work. Safe Boreas and Safe Scandinavia are laid up in Norway pending future work. Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to https://www.prosafe.com Stavanger, 19 April 2024 Prosafe SE For further information, please contact: Terje Askvig, CEO Phone: +47 952 03 886 Reese McNeel, CFO Phone: +47 415 08 186 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act